Biogen (BIIB) Cash from Investing Activities Growth (3y) (2012 - 2026)
Biogen (BIIB) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-78.48% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-32.26% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-4.78% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-12.88% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-62.97% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-36.21% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
60.61% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-38.13% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
39.65% |
| Date | Value |
|---|
| Mar 31, 2026 |
39.65% |
| Dec 31, 2025 |
-105.90% |
| Sep 30, 2025 |
-26.43% |
| Jun 30, 2025 |
-27.69% |
| Mar 31, 2025 |
58.21% |
| Dec 31, 2024 |
45.15% |
| Sep 30, 2024 |
-71.63% |
| Jun 30, 2024 |
71.62% |
| Mar 31, 2024 |
-0.67% |
| Dec 31, 2023 |
-57.68% |
| Sep 30, 2023 |
-221.56% |
| Jun 30, 2023 |
3.28% |
| Mar 31, 2023 |
-60.72% |
| Dec 31, 2022 |
-30.04% |
| Sep 30, 2022 |
87.29% |
| Jun 30, 2022 |
102.14% |
| Mar 31, 2022 |
-67.67% |
| Dec 31, 2021 |
58.92% |
| Sep 30, 2021 |
27.74% |
| Jun 30, 2021 |
48.96% |
